Hls Therapeutics Inc (HLS.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Sales | 14,085 | 14,519 | 12,473 | 15,863 | 16,037 |
| Cost of Goods | 2,235 | 2,303 | 1,774 | 2,533 | 1,870 |
| Gross Profit | 11,850 | 12,216 | 10,699 | 13,330 | 14,167 |
| Operating Expenses | 13,743 | 14,241 | 14,167 | 14,436 | 17,227 |
| Operating Income | -1,893 | -2,025 | -3,468 | -1,106 | -3,060 |
| Interest Expense | 2,452 | 2,707 | 2,625 | 2,613 | 2,292 |
| Other Income | -558 | 3,126 | -42 | -1,607 | -1,973 |
| Pre-tax Income | -4,903 | -1,606 | -6,135 | -5,326 | -7,325 |
| Income Tax | -59 | 4,076 | -29 | 75 | -424 |
| Net Income Continuous | -4,844 | -5,682 | -6,106 | -5,401 | -6,901 |
| Net Income | $-4,844 | $-5,682 | $-6,106 | $-5,401 | $-6,901 |
| EPS Basic Total Ops | -0.15 | -0.18 | -0.19 | -0.17 | -0.21 |
| EPS Basic Continuous Ops | -0.15 | -0.18 | -0.19 | -0.17 | -0.21 |
| EPS Diluted Total Ops | -0.15 | -0.18 | -0.19 | -0.17 | -0.21 |
| EPS Diluted Continuous Ops | -0.15 | -0.18 | -0.19 | -0.17 | -0.21 |
| EBITDA(a) | $3,057 | $6,957 | $2,409 | $4,334 | $3,174 |